Geron Corporation (GERN) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Geron Corporation (GERN) by buying shares or fractional shares at any major US broker, through a biotech or small-cap healthcare ETF that holds it, or as one holding in a thematic basket. Geron is a commercial-stage biopharmaceutical company built around Rytelo (imetelstat), a first-in-class telomerase inhibitor approved in the US and Europe for transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS). The thesis is a single-product commercial ramp plus optionality on a much larger myelofibrosis opportunity. The single biggest thing to understand is that Geron is essentially a one-drug story: its value hinges on how quickly Rytelo sells and on binary clinical readouts, so it carries far more risk than a diversified, profitable company.
GERN stock price
As of 2026-07-14, Geron Corporation (GERN) last closed at $1.40, up 4.9% over the past year. Over the past 52 weeks it has traded between $1.07 and $1.95.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Geron Corporation's investor relations page. Walnut is informational, not investment advice.
What does Geron Corporation (GERN) do?
Geron Corporation is a commercial-stage biopharmaceutical company whose entire business today rests on Rytelo (imetelstat), a first-in-class telomerase inhibitor. The FDA approved Rytelo in June 2024 for adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia and have not responded to, or are ineligible for, erythropoiesis-stimulating agents. In March 2025 the European Commission approved it across the EU and EEA for non-del(5q) lower-risk MDS. The approvals rest on the IMerge Phase 3 trial, which showed Rytelo reduced patients' need for red blood cell transfusions versus placebo. Geron reported roughly $184 million of Rytelo net revenue in 2025 and has guided to about $220 million to $240 million for 2026, with two consecutive quarters of demand growth reported through Q1 2026.
As a young commercial biotech, Geron is still building scale: it reported a small net loss in the first quarter of 2026 and held roughly $341 million in cash and marketable securities at the end of that quarter, giving it runway to fund the launch and its pipeline. The larger prize investors watch is myelofibrosis: the Phase 3 IMpactMF trial in relapsed or refractory myelofibrosis is fully enrolled, with an interim overall-survival analysis expected in the second half of 2026 and a final analysis in 2028. That readout is a binary catalyst that could sharply expand or deflate the story. Rytelo also carries a boxed-style safety profile common to this drug class, and its commercial success depends on where physicians place it relative to established options like Reblozyl.
What's driving Geron Corporation (GERN)?
1. Rytelo commercial ramp in lower-risk MDS
Geron's near-term value is driven by how fast Rytelo sells into second-line lower-risk MDS. The company reported about $184 million of 2025 revenue and guides to roughly $220 million to $240 million in 2026, with sequential demand growth. Inclusion in NCCN guidelines as a preferred second-line option after luspatercept failure supports uptake, but a single-product launch means every quarter of demand trends matters intensely to the story.
2. Myelofibrosis expansion via IMpactMF
The biggest optionality is myelofibrosis. The Phase 3 IMpactMF trial in relapsed or refractory myelofibrosis is fully enrolled, with an interim overall-survival analysis expected in the second half of 2026 and a final analysis in 2028. A positive readout could open a far larger market and reframe Geron as more than a lower-risk MDS name. A negative or ambiguous result would remove a major pillar of the bull case, making this a classic binary biotech catalyst.
3. Path toward profitability and cash runway
Geron entered 2026 still posting losses but narrowed its net loss to a few million dollars in Q1 2026 and held roughly $341 million in cash and marketable securities at quarter end. Management guides 2026 operating expenses of about $230 million to $240 million against rising Rytelo revenue. The trajectory toward breakeven, and whether the company can fund its launch and trials without heavy dilution, is a central part of the investment picture.
4. Label, guideline, and geographic expansion
Beyond the current indication, Geron benefits from broadening clinical recognition: NCCN guidelines name imetelstat as a preferred second-line option for lower-risk MDS after luspatercept failure, and the European approval opened EU and EEA markets. Deeper guideline positioning, real-world evidence, and international launch execution can extend the runway of the core MDS franchise even before any myelofibrosis decision arrives.
What are the risks to Geron Corporation (GERN)?
The dominant risk is single-product concentration: with essentially all revenue from one drug, any slowdown in the Rytelo launch, reimbursement pushback, or competitive pressure hits the whole company. Competition is real, as many physicians favor Reblozyl (luspatercept) frontline and reserve imetelstat for select patients, which caps the addressable pool. The IMpactMF myelofibrosis readout is a binary event that could sharply move the stock in either direction, and clinical trials can fail. Rytelo carries class-typical safety considerations, including cytopenias, that affect prescribing. As an unprofitable or barely profitable biotech, Geron may need to raise capital, risking dilution, and small-cap biotech stocks are historically volatile and sensitive to sentiment and single news events.
How is Geron Corporation (GERN) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Geron Corporation's investor relations page or your broker.
- Rytelo revenue (2025): About $184 million, the first roughly full year of the US launch
- 2026 revenue guidance: Roughly $220 million to $240 million, reflecting continued launch ramp
- Q1 2026 revenue: About $51.8 million, reported up sequentially with demand growth
- Profitability: Still around breakeven: reported a small net loss in Q1 2026 as launch and trial spending remain high
- Cash position: About $341 million in cash and marketable securities at the end of Q1 2026, funding launch and pipeline
- 2026 operating expenses (guidance): Roughly $230 million to $240 million, per company guidance
These figures are approximate and tied to the July 2026 asOf date; verify live numbers and current guidance before making any decision. For a commercial-stage biotech like Geron, traditional earnings multiples mean little because the company is only just approaching profitability. What matters more is the pace of Rytelo revenue growth, cash runway, and the outcome of the IMpactMF myelofibrosis trial. None of this is investment advice.
Who competes with Geron Corporation (GERN)?
Direct lower-risk MDS anemia therapies
Reblozyl (luspatercept), marketed by Bristol Myers Squibb, is the most important competitor. It is approved frontline for anemia in lower-risk MDS and is favored by many physicians for most patients, with imetelstat often reserved for those with high transfusion burden or after luspatercept failure. This positioning shapes how large Rytelo's addressable population is.
Established MDS treatment classes
Rytelo also competes with older standards of care in MDS, including erythropoiesis-stimulating agents (ESAs), immunomodulators such as Revlimid (lenalidomide), and hypomethylating agents such as Vidaza (azacitidine) and Dacogen (decitabine). These are widely used, familiar to prescribers, and often cheaper, which can slow adoption of a newer branded therapy.
Myelofibrosis and pipeline rivals
If Geron expands into myelofibrosis, it would enter a field with established and emerging players, including companies developing JAK inhibitors and other novel agents. Larger biopharma names such as Novartis and other pipeline competitors are active in myelofibrosis, so the future opportunity Geron is chasing is already contested.
How to invest in Geron Corporation (GERN)
There are three common ways to get GERN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so GERN sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where GERN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Geron Corporation (GERN)
Geron is a single-product biotech whose story is the Rytelo launch in lower-risk MDS plus a high-stakes myelofibrosis trial. It rewards a successful commercial ramp and positive readouts, and punishes a stumble on either. The question is how much binary, single-drug risk fits your portfolio.
Build a basket around GERN with Walnut
Use Geron Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is GERN a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a growing Rytelo launch, guideline support in lower-risk MDS, a funded balance sheet, and a potential myelofibrosis catalyst in the second half of 2026. The bear case is that Geron is essentially a one-drug biotech facing entrenched competition and binary trial risk, and small-cap biotech stocks are highly volatile. Weigh both against your portfolio.
What does Geron actually do?
+
Geron is a commercial-stage biopharmaceutical company. Its one approved product is Rytelo (imetelstat), a first-in-class telomerase inhibitor for transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS). The company sells Rytelo in the US and Europe and is running a Phase 3 trial to test the same drug in myelofibrosis, a different blood cancer.
What is Rytelo and why does it matter?
+
Rytelo (imetelstat) is Geron's only marketed drug and the source of essentially all its revenue. It is a telomerase inhibitor approved for certain lower-risk MDS patients with transfusion-dependent anemia after ESA therapy. Because Geron is a single-product company, Rytelo's sales trajectory and clinical expansion largely determine the stock's outcome.
Does Geron pay a dividend?
+
No. Geron is a commercial-stage biotech that is only just approaching profitability and reinvests its cash into launching Rytelo and funding clinical trials. Companies at this stage almost never pay dividends. Investors in GERN are betting on capital appreciation from revenue growth and pipeline success, not on income. Always check current filings before assuming any payout.
What is the IMpactMF trial and why is it important?
+
IMpactMF is Geron's fully enrolled Phase 3 trial testing imetelstat in relapsed or refractory myelofibrosis, a separate blood cancer from MDS. An interim overall-survival analysis is expected in the second half of 2026, with a final analysis in 2028. A positive result could open a much larger market, while a failure would remove a key pillar of the bull case. It is a binary catalyst.
What are the main risks of investing in GERN?
+
The central risk is single-product concentration: nearly all revenue comes from Rytelo, so any launch slowdown, reimbursement issue, or competitive loss hits the whole company. Reblozyl is favored frontline by many physicians, capping the addressable pool. The myelofibrosis readout is binary, trials can fail, and the company may need to raise capital, risking dilution. Small-cap biotech is historically volatile.
How does Geron compete with Reblozyl?
+
Reblozyl (luspatercept), from Bristol Myers Squibb, is approved frontline for anemia in lower-risk MDS and is favored by many physicians for most patients. Rytelo is often used in the second-line setting, and NCCN guidelines name imetelstat as a preferred second-line option after luspatercept failure. That positioning gives Geron a defined but narrower slice of the MDS market.
How can I get exposure to Geron through an ETF?
+
GERN appears in various biotech and small-cap healthcare ETFs, where it sits among many clinical- and commercial-stage drug developers. ETF exposure spreads single-stock risk across dozens or hundreds of holdings but dilutes how much any Geron move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to Geron specifically.
Is Geron profitable?
+
Not consistently yet. Geron narrowed its net loss to a few million dollars in the first quarter of 2026 as Rytelo revenue grew, but it is still investing heavily in the launch and its myelofibrosis trial. Management guides 2026 revenue of roughly $220 million to $240 million against operating expenses of about $230 million to $240 million, so the company is near breakeven rather than solidly profitable.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Geron Corporation's investor relations page or your broker before making investment decisions.